Product Details
| Product Name:
DCZ0415 |
CAS No.:
2242470-43-3 |
| Purity:
99.34% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | DCZ0415 |
| Description | DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity. |
| In vitro | DCZ0415 demonstrated significant anti-proliferative effects: it reduced colony formation at 10-20 μM (72 hours), decreased MM cell viability in a dose-dependent manner at 1.25-40 μM (72 hours), increased apoptotic cell death at 10-20 μM (24-72 hours), induced G0/G1 cell cycle arrest at 10-20 μM (24 hours), and reduced protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB at 10 μM (48 hours). The IC50 in MM cell lines was 1.0–10 μM, and DCZ0415 exerted cytotoxicity by inhibiting DNA synthesis in MM cells. |
| In vivo | DCZ0415, was confirmed to bind TRIP13 using pull-down, nuclear magnetic resonance spectroscopy, and surface plasmon resonance-binding assays.?DCZ0415 induced antimyeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant patients with myeloma.?The inhibitor impaired nonhomologous end joining repair and inhibited NF-κB activity.?Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic antimyeloma activity.?Therefore, targeting TRIP13 may be an effective therapeutic strategy for multiple myeloma, particularly refractory or relapsed multiple myeloma. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 62.5 mg/mL (175.35 mM), Sonication is recommended.
|
| Keywords | Apoptosis | inhibit | nonhomologous | Nuclear factor-κB | TRIP13 | Inhibitor | joining | end | drug-resistant | DCZ-0415 | myeloma | repair | DCZ0415 | anti-myeloma | DCZ 0415 | Nuclear factor-kappaB | NF-κB |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Glucosamine | Diallyl disulfide |
| Related Compound Libraries | Bioactive Compound Library | Antidepressant Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:667427-75-0
$178.00 / 1mg
-
CAS:54-71-7
$54.00 / 100mg
-
CAS:36338-96-2
$40.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$48.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States